知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

188 records (took 0.07 seconds)

    Method for producing antibodies
    3.
    发明授权
    Method for producing antibodies 有权
    产生抗体的方法

    公开(公告)号：US08084024B2

    公开(公告)日：2011-12-27

    申请号：US12375845

    申请日：2007-08-22

    Applicant: Charles Reay Mackay

    Inventor： Charles Reay Mackay

    IPC: A01N63/00 ,  A61K39/395 ,  A01K67/00

    CPC classification number: C07K14/70596 ,  A01K67/0278 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/00 ,  A01K2267/0368 ,  A61K2039/505 ,  A61K2039/5156 ,  C07K16/2896 ,  C07K2317/76 ,  C12N15/8509 ,  Y10S424/809

    Abstract: The present invention relates to a method for producing antibodies and to antibodies produced by this method. In one embodiment the invention relates to a method for producing an antibody that binds to a polypeptide of a first species, the method comprising immunizing a mammal of a second species with cells derived from a transgenic mammal of the second species, wherein the polypeptide of the first species is expressed on the surface of the cells derived from the transgenic mammal.

    Abstract translation: 本发明涉及一种生产抗体的方法以及通过该方法制备的抗体。 在一个实施方案中，本发明涉及用于产生结合第一物种多肽的抗体的方法，所述方法包括用衍生自第二物种的转基因哺乳动物的细胞免疫第二物种的哺乳动物，其中所述多肽 第一种在表达来自转基因哺乳动物的细胞表面表达。

    Reducing the immunogenicity of fusion proteins
    5.
    发明授权
    Reducing the immunogenicity of fusion proteins 有权
    降低融合蛋白的免疫原性

    公开(公告)号：US07973150B2

    公开(公告)日：2011-07-05

    申请号：US12552076

    申请日：2009-09-01

    Applicant: Stephen D. Gillies ,  Jeffrey Way ,  Anita A. Hamilton

    Inventor： Stephen D. Gillies ,  Jeffrey Way ,  Anita A. Hamilton

    IPC: C07H21/04

    CPC classification number: C07K1/1077 ,  C07K14/505 ,  C07K14/5434 ,  C07K14/55 ,  C07K14/70578 ,  C07K16/30 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/75 ,  C12N15/62 ,  Y10S424/809 ,  Y10S530/868

    Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.

    Abstract translation: 公开了用于产生具有降低的免疫原性的融合蛋白的组合物和方法。 本发明的融合蛋白包括具有降低连接表位结合II类MHC的能力的氨基酸变化的连接区，从而降低其与T细胞受体的相互作用。 本发明的方法涉及分析，改变或修饰融合蛋白的结合区域中的一个或多个氨基酸，以便鉴定T细胞表位并降低其与T细胞受体相互作用的能力。 本发明的组合物和方法在治疗中是有用的。

    Antibodies that specifically bind to neurokinin B
    6.
    发明授权
    Antibodies that specifically bind to neurokinin B 失效
    特异性结合神经激肽B的抗体

    公开(公告)号：US07514079B2

    公开(公告)日：2009-04-07

    申请号：US10981692

    申请日：2004-11-05

    Applicant: Craig A. Rosen ,  Steven M. Ruben

    Inventor： Craig A. Rosen ,  Steven M. Ruben

    IPC: A61K39/395 ,  G01N33/53 ,  C07K16/26

    CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/622 ,  Y10S424/80 ,  Y10S424/804 ,  Y10S424/806 ,  Y10S424/809 ,  Y10S435/975

    Abstract: The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including pre-eclampsia, hypertension, inflammation, asthma, gastrointestinal disorders, anxiety, depression, addiction, or pain. The invention also relates to nucleic acid molecules encoding anti-neurokinin B antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially pre-eclampsia, as well as hypertension, inflammation, asthma, gastrointestinal disorders, anxiety, depression, addiction, or pain, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to neurokinin B.

    Abstract translation: 本发明涉及与神经激肽B特异性结合的抗体和相关分子。这样的抗体具有例如用于预防和治疗癌症以及免疫系统疾病和病症，包括先兆子痫，高血压，炎症，哮喘， 胃肠道疾病，焦虑症，抑郁症，成瘾症或疼痛。 本发明还涉及编码抗神经激肽B抗体的核酸分子，含有这些核酸的载体和宿主细胞及其制备方法。 本发明涉及用于预防，检测，诊断，治疗或改善疾病或病症，特别是先兆子痫以及高血压，炎症，哮喘，胃肠道疾病，焦虑，抑郁，成瘾或疼痛的方法和组合物，其包括 向动物，优选人施用有效量的一种或多种特异性结合神经激肽B的抗体或其片段或变体或相关分子。

    Treatment of Hematologic Disorders
    7.
    发明申请
    Treatment of Hematologic Disorders 有权
    治疗血液病

    公开(公告)号：US20090028870A1

    公开(公告)日：2009-01-29

    申请号：US12185427

    申请日：2008-08-04

    Applicant: Megan Sykes ,  Thomas R. Spitzer

    Inventor： Megan Sykes ,  Thomas R. Spitzer

    IPC: A61K35/14 ,  A61K39/395 ,  A61P35/00 ,  A61P7/00

    CPC classification number: A61K39/39541 ,  A61K31/675 ,  A61K35/15 ,  A61K35/28 ,  A61K45/06 ,  Y10S424/809 ,  Y10S435/81 ,  Y10S514/885 ,  A61K2300/00

    Abstract: The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.

    Abstract translation: 本发明人已经发现，血液学障碍，例如肿瘤（血液癌）和非肿瘤性病症都可以通过使用骨髓来引导混合嵌合体来治疗，而不是骨髓切除术，调理。 本发明的方法降低GVHD，特别是与错配的同种异体或异种供体组织相关的GVHD，但提供例如显着的移植物抗白血病（GVL）效应等。

    Pharmaceutical composition of F(ab')2 antibody fragments
    10.
    发明申请
    Pharmaceutical composition of F(ab')2 antibody fragments 有权
    F（ab'）2抗体片段的药物组成

    公开(公告)号：US20040166107A1

    公开(公告)日：2004-08-26

    申请号：US10690639

    申请日：2003-10-23

    Inventor： Juan Lopez de Silanes ,  Rita G. Mancilla-Nava ,  Jorge F. Paniagua-Solis

    IPC: A61K039/395 ,  C12P021/06

    CPC classification number: C07K16/065 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/241 ,  C07K16/249 ,  C07K2317/54 ,  Y10S424/809

    Abstract: The present invention is directed to a pharmaceutical composition comprising F(abnull)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(abnull)2 antibody fragments using serum or blood plasma of a mammal that has been previously immunized as a source of antibodies. The serum or blood plasma is digested with an enzyme pepsin, followed by separation and purification until the pharmaceutical composition of F(abnull)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.

    Abstract translation: 本发明涉及包含优选不含白蛋白和完全抗体也基本上不含热原的F（ab'）2抗体片段和有效量的药学上可接受的载体的药物组合物。 还涉及使用先前已被免疫作为抗体来源的哺乳动物的血清或血浆来制备包含F（ab'）2抗体片段的药物组合物的方法。 用酶胃蛋白酶消化血清或血浆，然后分离和纯化，直到F（ab'）2片段的药物组合物不含白蛋白和完全抗体，基本上不含热原。

Patent Agency Ranking